Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics

Shu Ru Kuo, Salahaldin A. Tahir, Sanghee Park, Timothy C. Thompson, Scott Coffield, Arthur E. Frankel, Jen Sing Liu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Clinical studies have shown increased serum Cav-1 levels in patients with poor prognosis. In tissue culture and animal model experiments, blocking secreted Cav-1 by polyclonal antibodies inhibits tumor cell growth. Cav-1 is therefore a potential therapeutic target for prostate cancer treatment. In this study, we used Cav-1 knock-out mice as hosts to produce monoclonal anti-Cav-1 antibodies. A total of 11 hybridoma cell lines were selected for their ability to produce antibodies that bound GST-Cav-1 but not GST on glutathione-coated ELISA plates. Further screening with ELISAs using GST-Cav-1 fragments on GSH-coated plates classified these antibodies into four groups: N1-31 with five antibodies binds the far N-terminus between amino acids 1 and 31; N32-80 with three antibodies binds between amino acids 32 and 80; CSD with two antibodies potentially bind the scaffolding domain (amino acids 80-101); and Cav-1-C with 1 antibody binds parts of the C-terminal half. Binding affinities (Kd) of these antibodies to soluble Cav-1 ranged from 10 -11 to 10 -8 M. Binding competition experiments revealed that these antibodies recognized a total of six different epitopes on Cav-1. Potency of these antibodies to neutralize Cav-1-mediated signaling pathways in cultured cells and in animal models will be tested. A selected monoclonal antibody will then be humanized and be further developed into a potential anti-prostate cancer therapeutic.

Original languageEnglish (US)
Pages (from-to)77-86
Number of pages10
JournalHybridoma
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2012

Fingerprint

Caveolin 1
Anti-Idiotypic Antibodies
Prostatic Neoplasms
Antibodies
Therapeutics
Caveolae
Amino Acids
Neoplasms
Animal Models
Enzyme-Linked Immunosorbent Assay
Neoplasm Antibodies
Cellular Microenvironment
Antibody Affinity
Hybridomas
Endocytosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Kuo, S. R., Tahir, S. A., Park, S., Thompson, T. C., Coffield, S., Frankel, A. E., & Liu, J. S. (2012). Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma, 31(2), 77-86. https://doi.org/10.1089/hyb.2011.0100

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. / Kuo, Shu Ru; Tahir, Salahaldin A.; Park, Sanghee; Thompson, Timothy C.; Coffield, Scott; Frankel, Arthur E.; Liu, Jen Sing.

In: Hybridoma, Vol. 31, No. 2, 01.04.2012, p. 77-86.

Research output: Contribution to journalArticle

Kuo, SR, Tahir, SA, Park, S, Thompson, TC, Coffield, S, Frankel, AE & Liu, JS 2012, 'Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics', Hybridoma, vol. 31, no. 2, pp. 77-86. https://doi.org/10.1089/hyb.2011.0100
Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE et al. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma. 2012 Apr 1;31(2):77-86. https://doi.org/10.1089/hyb.2011.0100
Kuo, Shu Ru ; Tahir, Salahaldin A. ; Park, Sanghee ; Thompson, Timothy C. ; Coffield, Scott ; Frankel, Arthur E. ; Liu, Jen Sing. / Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. In: Hybridoma. 2012 ; Vol. 31, No. 2. pp. 77-86.
@article{6cd447e407dc4be9abb0ceec7ac8a2ab,
title = "Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics",
abstract = "Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Clinical studies have shown increased serum Cav-1 levels in patients with poor prognosis. In tissue culture and animal model experiments, blocking secreted Cav-1 by polyclonal antibodies inhibits tumor cell growth. Cav-1 is therefore a potential therapeutic target for prostate cancer treatment. In this study, we used Cav-1 knock-out mice as hosts to produce monoclonal anti-Cav-1 antibodies. A total of 11 hybridoma cell lines were selected for their ability to produce antibodies that bound GST-Cav-1 but not GST on glutathione-coated ELISA plates. Further screening with ELISAs using GST-Cav-1 fragments on GSH-coated plates classified these antibodies into four groups: N1-31 with five antibodies binds the far N-terminus between amino acids 1 and 31; N32-80 with three antibodies binds between amino acids 32 and 80; CSD with two antibodies potentially bind the scaffolding domain (amino acids 80-101); and Cav-1-C with 1 antibody binds parts of the C-terminal half. Binding affinities (Kd) of these antibodies to soluble Cav-1 ranged from 10 -11 to 10 -8 M. Binding competition experiments revealed that these antibodies recognized a total of six different epitopes on Cav-1. Potency of these antibodies to neutralize Cav-1-mediated signaling pathways in cultured cells and in animal models will be tested. A selected monoclonal antibody will then be humanized and be further developed into a potential anti-prostate cancer therapeutic.",
author = "Kuo, {Shu Ru} and Tahir, {Salahaldin A.} and Sanghee Park and Thompson, {Timothy C.} and Scott Coffield and Frankel, {Arthur E.} and Liu, {Jen Sing}",
year = "2012",
month = "4",
day = "1",
doi = "10.1089/hyb.2011.0100",
language = "English (US)",
volume = "31",
pages = "77--86",
journal = "Monoclonal Antibodies in Immunodiagnosis and Immunotherapy",
issn = "2167-9436",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics

AU - Kuo, Shu Ru

AU - Tahir, Salahaldin A.

AU - Park, Sanghee

AU - Thompson, Timothy C.

AU - Coffield, Scott

AU - Frankel, Arthur E.

AU - Liu, Jen Sing

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Clinical studies have shown increased serum Cav-1 levels in patients with poor prognosis. In tissue culture and animal model experiments, blocking secreted Cav-1 by polyclonal antibodies inhibits tumor cell growth. Cav-1 is therefore a potential therapeutic target for prostate cancer treatment. In this study, we used Cav-1 knock-out mice as hosts to produce monoclonal anti-Cav-1 antibodies. A total of 11 hybridoma cell lines were selected for their ability to produce antibodies that bound GST-Cav-1 but not GST on glutathione-coated ELISA plates. Further screening with ELISAs using GST-Cav-1 fragments on GSH-coated plates classified these antibodies into four groups: N1-31 with five antibodies binds the far N-terminus between amino acids 1 and 31; N32-80 with three antibodies binds between amino acids 32 and 80; CSD with two antibodies potentially bind the scaffolding domain (amino acids 80-101); and Cav-1-C with 1 antibody binds parts of the C-terminal half. Binding affinities (Kd) of these antibodies to soluble Cav-1 ranged from 10 -11 to 10 -8 M. Binding competition experiments revealed that these antibodies recognized a total of six different epitopes on Cav-1. Potency of these antibodies to neutralize Cav-1-mediated signaling pathways in cultured cells and in animal models will be tested. A selected monoclonal antibody will then be humanized and be further developed into a potential anti-prostate cancer therapeutic.

AB - Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Clinical studies have shown increased serum Cav-1 levels in patients with poor prognosis. In tissue culture and animal model experiments, blocking secreted Cav-1 by polyclonal antibodies inhibits tumor cell growth. Cav-1 is therefore a potential therapeutic target for prostate cancer treatment. In this study, we used Cav-1 knock-out mice as hosts to produce monoclonal anti-Cav-1 antibodies. A total of 11 hybridoma cell lines were selected for their ability to produce antibodies that bound GST-Cav-1 but not GST on glutathione-coated ELISA plates. Further screening with ELISAs using GST-Cav-1 fragments on GSH-coated plates classified these antibodies into four groups: N1-31 with five antibodies binds the far N-terminus between amino acids 1 and 31; N32-80 with three antibodies binds between amino acids 32 and 80; CSD with two antibodies potentially bind the scaffolding domain (amino acids 80-101); and Cav-1-C with 1 antibody binds parts of the C-terminal half. Binding affinities (Kd) of these antibodies to soluble Cav-1 ranged from 10 -11 to 10 -8 M. Binding competition experiments revealed that these antibodies recognized a total of six different epitopes on Cav-1. Potency of these antibodies to neutralize Cav-1-mediated signaling pathways in cultured cells and in animal models will be tested. A selected monoclonal antibody will then be humanized and be further developed into a potential anti-prostate cancer therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=84859969455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859969455&partnerID=8YFLogxK

U2 - 10.1089/hyb.2011.0100

DO - 10.1089/hyb.2011.0100

M3 - Article

C2 - 22509911

AN - SCOPUS:84859969455

VL - 31

SP - 77

EP - 86

JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

SN - 2167-9436

IS - 2

ER -